PHARMA NORD EXPORT ApS: Financial statements 2023
CVR: 70996510
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
PHARMA NORD EXPORT ApS (CVR 70996510) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 1,442,161 and a net result of DKK 6,301,578 compared with DKK 2,109,599 the year before. That is a decrease of 10.7% compared with the year before. Equity in the 2023 report amounted to DKK 37,383,759. The solvency ratio was 59.3%. The company had 65 employees in the financial year.
- Gross Profit
- DKK 1,442,161
- Profit/Loss
- DKK 6,301,578
- Equity
- DKK 37,383,759
- Total Assets
- DKK 63,064,101
- Employees
- 65
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 1.4 mio. | 6.3 mio. | 37.4 mio. | 65 |
| 2022 | - | 1.6 mio. | 2.1 mio. | 46 mio. | 63 |
| 2021 | - | 1.7 mio. | 3.2 mio. | 43.9 mio. | 49 |
| 2020 | - | 2.2 mio. | 2.7 mio. | 40.8 mio. | 48 |
| 2019 | - | 2 mio. | -583 t. | 73.1 mio. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
PHARMA NORD EXPORT ApS has published its annual report for 2022. Gross profit came to DKK 1,614,118, and the net result was DKK 2,109,599.
About PHARMA NORD EXPORT ApS
PHARMA NORD EXPORT ApS is a Danish company of the type Anpartsselskab based in Vejle, founded in 1982. The company is registered under the industry Engroshandel med andre fødevarer. The company was previously named TRAUDE SCHNEIDER ASTROFAKTA-DANMARK ApS. The management consists of Eli Wallin. The board consists of Michael Christiani Havemann (chair) and Eli Wallin. The company is owned by PHARMCO II ApS and PharmCo III ApS. According to the 2025 annual report, the company had an average of 66 employees. In 2025, the company reported a gross profit of DKK 1,575,000 and a net result of DKK 11,516,000 compared with DKK 6,889,205 the year before. Equity in the 2025 report amounted to DKK 46,928,000.